The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment

被引：40

作者：

Holubec, Lubos ^{[1
,4
]}

Polivka, Jiri, Jr. ^{[1
,2
]}

Safanda, Martin ^{[4
]}

Karas, Michal ^{[3
]}

Liska, Vaclav ^{[1
]}

机构：

[1] Charles Univ Prague, Biomed Ctr, Fac Med Plzen, Plzen, Czech Republic

[2] Charles Univ Prague, Dept Histol & Embryol, Fac Med Plzen, Plzen, Czech Republic

[3] Charles Univ Prague, Dept Hematol & Oncol, Fac Med Plzen, Plzen, Czech Republic

[4] Na Homolce Hosp, Dept Clin Oncol, Prague, Czech Republic

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 09期

关键词：

Colorectal cancer; cetuximab; immune response; targeted therapy; immunomodulation; review; GAMMA RECEPTOR POLYMORPHISMS; CHECKPOINT INHIBITORS; MONOCLONAL-ANTIBODIES; THERAPY; EGFR; IMMUNOTHERAPY; PANITUMUMAB; SURVIVAL; MICROENVIRONMENT; CYTOTOXICITY;

D O I：

10.21873/anticanres.10985

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so far been associated with combined chemotherapy or radiation. It has been shown that these treatment strategies have their clinical limitations and do not fully exploit the immunomodulatory effect of these drugs. In this review, we discuss the mechanisms of immunomodulation together with the anticancer immune response to the monoclonal antibodies targeted to the EGFR. The combination of anti-EGFR monoclonal antibodies with other immunotherapeutic treatment modalities certainly brings new opportunities for targeted therapy in patients with colorectal cancer.

引用

页码：4421 / 4426

页数：6

共 50 条

[1] Cetuximab in the treatment of patients with colorectal cancer
Garrett, Christopher R.
Eng, Cathy
EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (07) : 937 - 949
[2] Emerging Role of Cetuximab in the Treatment of Colorectal Cancer
Papa, Anselmo
Rossi, Luigi
Lo Russo, Giuseppe
Giordani, Erika
Spinelli, Gian Paolo
Zullo, Angelo
Petrozza, Vincenzo
Tomao, Silverio
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2012, 7 (02) : 233 - 247
[3] The Role of Cetuximab in the Treatment of Metastatic Colorectal Cancer
Holubec, Lubos
Liska, Vaclav
Matejka, Vit M.
Fiala, Ondrej
Dreslerova, Jana
Mrazkova, Petra
Treska, Vladislav
Finek, Jindrich
ANTICANCER RESEARCH, 2012, 32 (09) : 4007 - 4011
[4] Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer
Galal, K. M.
Khaled, Z.
Mourad, Abdel Monem M.
INDIAN JOURNAL OF CANCER, 2011, 48 (01) : 47 - 54
[5] Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer
Wang, Lin
Wei, Yingfeng
Fang, Weijia
Lu, Chong
Chen, Jianing
Cui, Guangying
Diao, Hongyan
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 44 (03) : 1038 - 1050
[6] Cetuximab in the treatment of metastatic colorectal cancer
Moosmann, Nicolas
Heinemann, Volker
EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (02) : 243 - 256
[7] EGFR-targeted therapy in colorectal cancer: Does immunohistochemistry deserve a role in predicting the response to cetuximab?
Valentini, Anna Maria
Pirrelli, Michele
Caruso, Maria Lucia
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2008, 10 (02) : 124 - 131
[8] Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
Krawczyk, Pawel Adam
Kowalski, Dariusz M.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2014, 18 (01): : 7 - 16
[9] Cetuximab for treatment of metastatic colorectal cancer
Cerea, G.
Ricotta, R.
Schiavetto, I.
Maugeri, M. R.
Sartore-Bianchi, A.
Moroni, M.
Artale, S.
Siena, S.
ANNALS OF ONCOLOGY, 2006, 17 : VII66 - VII67
[10] Cetuximab for the treatment of patients with colorectal cancer
Cassidy, J.
NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (06): : 310 - 311

← 1 2 3 4 5 →